GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003009933 | Thyroid | ATC | myeloid cell differentiation | 170/6293 | 381/18723 | 4.26e-06 | 4.68e-05 | 170 |
GO:004506926 | Thyroid | ATC | regulation of viral genome replication | 49/6293 | 85/18723 | 4.54e-06 | 4.97e-05 | 49 |
GO:001402017 | Thyroid | ATC | primary neural tube formation | 53/6293 | 94/18723 | 4.69e-06 | 5.11e-05 | 53 |
GO:000940832 | Thyroid | ATC | response to heat | 60/6293 | 110/18723 | 4.89e-06 | 5.32e-05 | 60 |
GO:003288613 | Thyroid | ATC | regulation of microtubule-based process | 114/6293 | 240/18723 | 5.17e-06 | 5.59e-05 | 114 |
GO:003105811 | Thyroid | ATC | positive regulation of histone modification | 52/6293 | 92/18723 | 5.21e-06 | 5.61e-05 | 52 |
GO:003450212 | Thyroid | ATC | protein localization to chromosome | 52/6293 | 92/18723 | 5.21e-06 | 5.61e-05 | 52 |
GO:003221017 | Thyroid | ATC | regulation of telomere maintenance via telomerase | 34/6293 | 53/18723 | 5.22e-06 | 5.61e-05 | 34 |
GO:001083326 | Thyroid | ATC | telomere maintenance via telomere lengthening | 47/6293 | 81/18723 | 5.53e-06 | 5.93e-05 | 47 |
GO:1902041110 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 32/6293 | 49/18723 | 5.63e-06 | 6.00e-05 | 32 |
GO:000018422 | Thyroid | ATC | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 26/6293 | 37/18723 | 5.64e-06 | 6.00e-05 | 26 |
GO:003312033 | Thyroid | ATC | positive regulation of RNA splicing | 26/6293 | 37/18723 | 5.64e-06 | 6.00e-05 | 26 |
GO:00315774 | Thyroid | ATC | spindle checkpoint | 27/6293 | 39/18723 | 5.83e-06 | 6.16e-05 | 27 |
GO:00519854 | Thyroid | ATC | negative regulation of chromosome segregation | 30/6293 | 45/18723 | 5.89e-06 | 6.18e-05 | 30 |
GO:19058194 | Thyroid | ATC | negative regulation of chromosome separation | 30/6293 | 45/18723 | 5.89e-06 | 6.18e-05 | 30 |
GO:001077023 | Thyroid | ATC | positive regulation of cell morphogenesis involved in differentiation | 46/6293 | 79/18723 | 6.09e-06 | 6.38e-05 | 46 |
GO:005254734 | Thyroid | ATC | regulation of peptidase activity | 200/6293 | 461/18723 | 6.25e-06 | 6.52e-05 | 200 |
GO:200123729 | Thyroid | ATC | negative regulation of extrinsic apoptotic signaling pathway | 54/6293 | 97/18723 | 6.41e-06 | 6.68e-05 | 54 |
GO:000184316 | Thyroid | ATC | neural tube closure | 50/6293 | 88/18723 | 6.43e-06 | 6.68e-05 | 50 |
GO:009872722 | Thyroid | ATC | maintenance of cell number | 70/6293 | 134/18723 | 6.45e-06 | 6.69e-05 | 70 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513014 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513015 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2 | SNV | Missense_Mutation | novel | c.1390N>T | p.Ala464Ser | p.A464S | P00734 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | rs121918482 | c.1292N>A | p.Arg431His | p.R431H | P00734 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | | c.448N>T | p.Ala150Ser | p.A150S | P00734 | protein_coding | tolerated(0.47) | benign(0.06) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2 | insertion | In_Frame_Ins | novel | c.1074_1075insACCCAGCATGAGCTTTCCTGGGATTACTCATAT | p.Ser358_Tyr359insThrGlnHisGluLeuSerTrpAspTyrSerTyr | p.S358_Y359insTQHELSWDYSY | P00734 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
F2 | deletion | Frame_Shift_Del | | c.1015_1025delNNNNNNNNNNN | p.Pro340GlufsTer55 | p.P340Efs*55 | P00734 | protein_coding | | | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
F2 | deletion | Frame_Shift_Del | novel | c.204delN | p.Glu69ArgfsTer52 | p.E69Rfs*52 | P00734 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
F2 | SNV | Missense_Mutation | rs144785536 | c.103C>T | p.Arg35Trp | p.R35W | P00734 | protein_coding | tolerated(0.11) | benign(0.093) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.1755N>T | p.Met585Ile | p.M585I | P00734 | protein_coding | tolerated(0.47) | benign(0.011) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.225N>C | p.Glu75Asp | p.E75D | P00734 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
F2 | SNV | Missense_Mutation | rs775306348 | c.5C>T | p.Ala2Val | p.A2V | P00734 | protein_coding | tolerated_low_confidence(0.14) | benign(0.01) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Anisindione | ANISINDIONE | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | LEPIRUDIN | LEPIRUDIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | ATryn antithrombin | | 24391399 |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | (-)-EPICATECHIN | (-)-EPICATECHIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | hormonal contraceptives for systemic use | | 15208046,28750087,12069454,16769590 |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Odiparcil | ODIPARCIL | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | QUERCETIN | QUERCETIN | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | AZD-0837 | ATECEGATRAN METOXIL | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | | Hirudin | | |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178102998 | DABIGATRAN | |